SARS-CoV-2感染与新发甲状腺疾病风险升高相关:4.5年观察性研究
该研究在Montefiore医疗系统纳入无既往甲状腺疾病者,比较COVID-19住院、非住院患者与同期COVID阴性对照及历史对照,采用Cox回归联合逆概率加权评估新发甲状腺疾病风险。结果显示住院与非住院COVID-19患者新发各类甲状腺疾病风险均升高,提示COVID-19康复者或需加强甲状腺功能筛查。
要点
- 住院COVID-19患者新发各类甲状腺疾病风险约为同期COVID阴性对照的2倍
- 非住院COVID-19患者新发甲状腺疾病风险亦升高,幅度低于住院患者
- 建议对COVID-19康复者考虑加强甲状腺功能筛查
核心结论
- SARS-CoV-2感染与住院及非住院患者新发各类甲状腺疾病风险升高相关,提示COVID-19康复者或需加强甲状腺功能筛查。
研究设计与样本
- 主要分析采用Cox回归联合逆概率加权(IPW),敏感性分析包括多因素调整、1:1倾向评分匹配及与历史对照比较。
主要发现
- 与同期COVID阴性对照相比,住院COVID-19患者全部甲状腺疾病风险升高(IPW调整HR=2.11 [2.03-2.19])。
- 住院COVID-19患者甲状腺功能减退症HR=2.02 [1.92-2.12],甲状腺功能亢进症HR=2.31 [2.13-2.50],其他/未特指甲状腺疾病HR=2.27 [2.12-2.43]。
- 非住院COVID-19患者全部甲状腺疾病HR=1.40 [1.35-1.46],甲状腺功能减退症HR=1.37 [1.31-1.43],甲状腺功能亢进症HR=1.56 [1.45-1.68],其他/未特指甲状腺疾病HR=1.42 [1.34-1.51]。
- 敏感性分析与主要结果一致;非住院队列与历史对照比较时风险估计有所减弱。
关键数值与推荐
- 结局包括新发甲状腺疾病、甲状腺功能减退症、甲状腺功能亢进症、其他/未特指甲状腺疾病,以及促甲状腺激素(TSH)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)水平。
临床怎么用
- 对COVID-19康复者,尤其住院患者,可考虑加强甲状腺功能筛查以早期发现甲状腺功能异常。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Thyroid disease has been reported as a complication associated with acute SARS-CoV-2 infection. OBJECTIVE: This study evaluated the long-term risk of incident thyroid dysfunction after COVID-19 in patients without preexisting thyroid disease. METHODS: Patients without prior thyroid disease were grouped into 15 372 individuals hospitalized with COVID-19, 41 757 nonhospitalized individuals with COVID-19, 343 348 contemporary COVID-negative controls (March 1, 2020-August 17, 2024), and 171 141 historical controls (January 1, 2016-December 31, 2019) within the Montefiore Health System. Outcomes included new-onset thyroid disease, hypothyroidism, hyperthyroidism, and other/unspecified thyroid disease, and thyrotropin (TSH), free 3,5,3'-triiodothyronine (FT3), and free thyroxine (FT4) levels. The primary analysis used Cox regression with inverse probability weighting (IPW). Sensitivity analyses included multivariate adjustment, 1:1 propensity score matching, and comparisons with historical controls. RESULTS: Compared to contemporary COVID-negative controls, patients hospitalized for COVID-19 had significantly higher risk of all thyroid disease (IPW-adjusted hazard ratio (HR) = 2.11 [2.03-2.19]), hypothyroidism (HR = 2.02 [1.92-2.12]), hyperthyroidism (HR = 2.31 [2.13-2.50]), and other/unspecified thyroid disease (HR = 2.27 [2.12-2.43]). Nonhospitalized COVID-positive patients also had increased risk of all thyroid disease (HR = 1.40 [1.35-1.46]), hypothyroidism (HR = 1.37 [1.31-1.43]), hyperthyroidism (HR = 1.56 [1.45-1.68]), and other/unspecified thyroid disease (HR = 1.42 [1.34-1.51]). Sensitivity analyses were consistent with the main findings. Estimates of risks were attenuated in the nonhospitalized cohort when compared to historical controls. CONCLUSION: SARS-CoV-2 infection is associated with an increased risk of all forms of new-onset thyroid disease investigated both in hospitalized and nonhospitalized patients. These findings suggest that enhanced screening for thyroid dysfunction may be warranted among individuals recovering from COVID-19.
引用
- Mehrotra-Varma S, Hadidchi R, Henry SS, et al. Elevated Risk of New-Onset Thyroid Disease Associated With SARS-CoV-2 Infection: A 4.5-Year Observational Study. J Clin Endocrinol Metab. 2026. PMID: 41433356. doi:10.1210/clinem/dgaf688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。